Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03547427 · ClinicalTrials.gov registry record · NA
Glucagon Counterregulation in Type 1 Diabetes
A NA study, sponsored by University of Virginia.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT03547427 is a NA study that was terminated before completion, run by University of Virginia. The registered enrollment target is 13 participants.
The verdict
NCT03547427, a NA study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether the combination of insulin and pramlintide is better than insulin alone at helping the pancreas release glucagon in response to a low blood sugar episode. A secondary goal is to assess whether basal pramlintide will delay gastric emptying.
Interventions
- OTHER CGM
- OTHER Basal insulin alone
- OTHER Basal pramlintide and reduced basal insulin
- OTHER Acetaminophen test
- OTHER Insulin-induced hypoglycemia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-05-20 |
| Est. Completion | 2019-03-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03547427
The ClinicalTrials.gov registry entry for NCT03547427 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CGM is the first listed.
NCT03547427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03547427 about?
NCT03547427 is a clinical study titled "Glucagon Counterregulation in Type 1 Diabetes". The purpose of this study is to find out whether the combination of insulin and pramlintide is better than insulin alone at helping the pancreas release glucagon in response to a low blood sugar episode. A secondary goal is to assess whether basal pramlintide will delay gastric emptying.
What is the current status of trial NCT03547427?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2018-05-20. Estimated completion is 2019-03-11.
What interventions are being tested in trial NCT03547427?
The interventions under investigation include: CGM (OTHER), Basal insulin alone (OTHER), Basal pramlintide and reduced basal insulin (OTHER), Acetaminophen test (OTHER), Insulin-induced hypoglycemia (OTHER).
Who is sponsoring clinical trial NCT03547427?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.